- Tuesday, April 29, 2025 @ 9:00 am
Ymmunobio AG announced the successful completion of preclinical proof-of-concept studies for its ADCs, YB-800ADC1 and YB-800ADC2. Both demonstrated strong anti-tumor efficacy, achieving 90% tumor growth inhibition. This milestone advances Ymmunobio’s ADC program toward clinical development, addressing critical unmet needs in solid tumors with a novel, first-in-class target.
Ymmunobio AG (YB), a Swiss-based global biotech company dedicated to developing new cancer therapeutics, announces that its two antibody drug conjugate (ADC) assets, YB-800ADC1 and YB-800ADC2, have completed the preclinical proof of concept studies. Both in vivo and in vitro studies have reached this important milestone by demonstrating the anti-tumor efficacy of both ADCs.
The ADCs are derived from YB’s lead antibody, YB-800, which targets a novel and first-in-class tumor marker. They utilize established payloads and a third-generation linker, demonstrating a 90% inhibition of tumor growth.
“These excellent results allow YB to move forward swiftly to prepare for the pivotal toxicology studies. This is a major step towards the clinical development of our ADCs in solid tumors and demonstrates the potential for YB’s ADCs to address unmet needs for cancer patients expressing the new novel tumor marker. In addition, the proof of concept data support the preclinical development of the two YB-800 based radiopharmaceuticals developed in collaboration with the Paul Scherer Institute,” said Peter Schiemann, CEO.
